Description:
GLYCOGEN STORAGE DISEASE III
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases |
| Class |
Disorders of Carbohydrate Metabolism |
|
Cell Type
|
Fibroblast
|
|
Transformant
|
Untransformed
|
|
Race
|
White
|
|
Ethnicity
|
LATIN AMERICAN
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Clinical summary/Case history
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| Passage Frozen |
18 |
| |
| amylo-alpha-1,6-glucosidase |
According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.2.1.33 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase Isoenzyme Electrophoresis |
| |
| Remarks |
Latin-American; deficient debrancher enzyme activity |
| Gene Ontology |
GO:0004134 4-alpha-glucanotransferase activity |
|
GO:0004135 amylo-alpha-1,6-glucosidase activity |
|
GO:0005975 carbohydrate metabolism |
|
GO:0005978 glycogen biosynthesis |
|
GO:0016757 transferase activity, transferring glycosyl groups |
|
GO:0016798 hydrolase activity, acting on glycosyl bonds |
|
GO:0043033 isoamylase complex |
| NCBI Gene |
Gene ID:178 |
| NCBI GTR |
232400 GLYCOGEN STORAGE DISEASE III; GSD3 |
| OMIM |
232400 GLYCOGEN STORAGE DISEASE III; GSD3 |
| Omim Description |
AMYLO-1,6-GLUCOSIDASE DEFICIENCY; AGL DEFICIENCY |
| |
CORI DISEASE |
| |
FORBES DISEASE |
| |
GLYCOGEN DEBRANCHER DEFICIENCY; GDE DEFICIENCY |
| |
GLYCOGEN DEBRANCHER ENZYME, INCLUDED; GDE, INCLUDED |
| |
GLYCOGEN DEBRANCHING DEFICIENCYAMYLO-1,6-GLUCOSIDASE, 4-ALPHA-GLUCANOTRANSFERASE, INCLUDED; AGL,INCLUDED |
| |
GLYCOGEN STORAGE DISEASE III |
| |
LIMIT DEXTRINOSIS |
| Passage Frozen |
18 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not inactivated |
| Substrate |
None specified |
| Subcultivation Method |
trypsin-EDTA |
| Supplement |
- |
|